Chan T, Juneja S, Wolf M, Januszewicz E, Cooper I
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia.
Bone Marrow Transplant. 1994 Feb;13(2):145-8.
We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 months after the diagnosis of SMDS. Our cases support the view that there is an increased risk of SMDS/acute leukemia following autologous marrow transplantation.
我们报告了两例继发性骨髓增生异常综合征(SMDS),这两例患者在接受高剂量化疗并回输自体干细胞支持下成功治疗原发性恶性肿瘤后发生了该综合征。分别在自体移植后24个月和40个月诊断出SMDS。两名患者在诊断出SMDS后均存活了7个月。我们的病例支持这样一种观点,即自体骨髓移植后发生SMDS/急性白血病的风险增加。